A Clinical Study to Evaluate the Efficacy of Siddha Medicines in Bronchial Asthma

A Single-Centric, Single-Arm Pilot Study to Evaluate the Safety and Efficacy of Swasa Kudori Chooranam (SKC) In the Management of Swasa Kaasam (Bronchial Asthma) - SKC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064944

Enrollment

Registered

2024-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J452- Mild intermittent asthma Health Condition 2: J453- Mild persistent asthma Health Condition 3: J454- Moderate persistent asthma

Interventions

Intervention1: Swasa Kudori Chooranam: 1 gram of chooranam with honey, TDS, after food, orally for 30 days. Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1. Symptoms of dry cough, recurrent attacks of dyspnoea, hoarseness of voice, tightness of chest, profuse sweating, and wheezing 2. Asthmatic attack due to seasonal changes and allergens 3. Willing to take radiological investigation and provide blood samples for lab investigation. 4. FEV1 with 50-80%

Exclusion criteria

Exclusion criteria: 1. Asthma associated with COPD 2. Unstable bronchial asthma or status asthmaticus. 3. Asthma exacerbation during the past month. 4. COVID 19 Positive patients (on the time of recruitment). 5. Tuberculosis, Pneumonia, and Bronchogenic carcinoma 6. Cardiac, Liver and Renal Diseases. 7. Participation in another clinical trial within the preceding 90 days of the study starts. 8. Pregnant and lactating women. 9. Subjects with a continuing history of Alcohol, Smoking or Drug Abuse.

Design outcomes

Primary

Measure	Time frame
1. Effect of the trial drug will be assessed by Mean Improvement in Pulmonary Function Test, Asthma Control Test and MMRC Dyspnoea Scale from baseline. 2. Effect of the trial drug will be assessed by Mean Improvement in Quality of Life of trial participants assessed by Asthma Quality of Life Questionnaire with Standardized Activities from baseline.Timepoint: PFT, Asthma Control Test, MMRC Dyspnoea Scale and Asthma Quality of Life Questionnaire will be done on Day 0,16,31 and 121	—

Measure

Time frame

1. Effect of the trial drug will be assessed by Mean Improvement in Pulmonary Function Test, Asthma Control Test and MMRC Dyspnoea Scale from baseline. 2. Effect of the trial drug will be assessed by Mean Improvement in Quality of Life of trial participants assessed by Asthma Quality of Life Questionnaire with Standardized Activities from baseline.Timepoint: PFT, Asthma Control Test, MMRC Dyspnoea Scale and Asthma Quality of Life Questionnaire will be done on Day 0,16,31 and 121

—

Secondary

Measure	Time frame
1. Safety of the study drug will be assessed by using following parameters: LFT, RFT, CRP and Urine routine on 0 day, 31st day and 121st day. 2. Effect of the trial drug will be assessed by Mean improvement in reducing the frequency of using allopathic drugs for acute asthmatic attacks.Timepoint: Will be done on Day 0, 31 and 121	—

Countries

India

Contacts

Public ContactDr A Lavanya

Siddha Regional Research Institute

dr.s.s.ram28@gmail.com8608533131

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026